Stevanato Group S.p.A.
- Open
- 21.28
- Day high
- 21.62
- Day low
- 20.93
- Prev close
- 21.03
- Volume
- 336K
- Mkt cap
- $5.9B
- P/E (TTM)
- 38.6
- EPS (TTM)
- $0.56
- P/B
- 3.3
- P/S
- 4.1
- Yield
- 0.29%
- Per share
- $0.06
- ▼Insiders net selling -$268K over the last 3 months (0 open-market buys, 7 sales)
- 🏛Institutions mixed (13F)
Stevanato Group S.p.A. (STVN) is a Healthcare company listed on NYSE. The stock is down 6% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 7 sales (SEC Form 4). Drillr has 1 published research article covering STVN.
Stevanato Group S.p.A. (STVN) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
STVN earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 4, 2026 | $0.14 | $0.16 | +10.5% | $345M | +1.3% |
| May 7, 2026 | $0.12 | $0.13 | +8.3% | $316M | +1.8% |
| Mar 4, 2026 | $0.20 | $0.21 | +5.0% | $403M | +28.2% |
| Nov 6, 2025 | $0.14 | $0.16 | +14.3% | $355M | -7.9% |
| May 8, 2025 | $0.10 | $0.11 | +10.0% | $281M | -6.7% |
| Mar 6, 2025 | $0.20 | $0.20 | +0.0% | $342M | +27.7% |
| May 9, 2024 | $0.12 | $0.09 | -27.3% | $254M | -15.6% |
| Mar 7, 2024 | $0.21 | $0.20 | -5.3% | $353M | +24.1% |
| Oct 31, 2023 | $0.16 | $0.16 | +0.0% | $286M | -25.5% |
| Jul 28, 2023 | $0.14 | $0.15 | +7.7% | $279M | -17.1% |
| May 4, 2023 | $0.13 | $0.12 | -8.3% | $259M | -12.8% |
| Mar 2, 2023 | $0.17 | $0.19 | +12.5% | $315M | +14.3% |
STVN insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 10, 2026 | Santel Lucianodirector | Sell | 2,023 | $20.09 |
| Aug 10, 2026 | Dal Lago Marcoofficer: Chief Financial Officer | Sell | 4,209 | $20.09 |
| Aug 10, 2026 | Magistretti Elisabettadirector | Sell | 2,045 | $20.09 |
| Jun 26, 2026 | Dal Lago Marcoofficer: Chief Financial Officer | Option | 7,997 | — |
| Jun 26, 2026 | Dal Lago Marcoofficer: Chief Financial Officer | Option | 2,770 | — |
| Jun 26, 2026 | Dal Lago Marcoofficer: Chief Financial Officer | Option | 2,924 | — |
| Jun 26, 2026 | Dal Lago Marcoofficer: Chief Financial Officer | Option | 2,303 | — |
| Jun 26, 2026 | LIN SUE-JEANdirector | Grant | 4,975 | — |
| Jun 26, 2026 | MOREL DONALD E JRdirector | Grant | 4,975 | — |
| Jun 26, 2026 | MOREL DONALD E JRdirector | Sell | 1,493 | $17.09 |
| Jun 26, 2026 | Santel Lucianodirector | Grant | 4,975 | — |
| Jun 26, 2026 | Magistretti Elisabettadirector | Grant | 4,975 | — |
| Jun 26, 2026 | Balachandran Madhavandirector | Grant | 4,975 | — |
| Jun 26, 2026 | Stocchi Mauroofficer: See Remarks | Option | 6,586 | — |
| Jun 26, 2026 | Stocchi Mauroofficer: See Remarks | Option | 2,470 | — |
Source: STVN SEC Form 4 filings, latest Aug 10, 2026. For informational purposes only — not investment advice.
See the full STVN insider & 13F page →Stevanato Group S.p.A. company profile
Overview
Stevanato Group S.p.A. (NYSE:STVN) is an Italian pharmaceutical packaging and equipment company founded in 1949 and headquartered in Piombino Dese, Italy. The company went public in July 2021 and operates as a subsidiary of Stevanato Holding S.R.L. Stevanato has evolved from a traditional glass manufacturer into a leading provider of integrated solutions for the pharmaceutical and healthcare industries, specializing in drug containment, delivery systems, and manufacturing equipment. The company serves global pharmaceutical companies through manufacturing facilities in Italy, the United States, and other international locations.
Business
Stevanato Group operates in the pharmaceutical packaging and equipment industry, providing critical infrastructure and solutions that enable drug manufacturers to safely contain, deliver, and produce their products. The pharmaceutical packaging industry is essential because drugs must be stored in specialized containers that maintain their stability, prevent contamination, and enable precise dosing - requirements that are particularly stringent for biologics and other advanced therapies. The company operates through two main business segments. The Biopharmaceutical and Diagnostic Solutions (BDS) segment represents approximately 80-85% of total revenue and focuses on drug containment and delivery systems. This includes glass vials (both bulk and ready-to-use), prefillable syringes, cartridges for pen injectors, and specialized containers for biologics. Within this segment, "high-value solutions" - which are more complex, ready-to-use products requiring specialized manufacturing processes - represent about 47% of BDS revenue and are growing rapidly at 15-25% annually. The Engineering segment accounts for roughly 15-20% of revenue and provides manufacturing equipment to pharmaceutical companies. This includes glass forming machines that create the containers, visual inspection systems that ensure quality control, and assembly/packaging equipment that prepares final products. The Engineering segment also offers analytical services and validation support to help pharmaceutical companies meet regulatory requirements. The company's products are particularly important for biologics - complex drugs derived from living organisms that include vaccines, monoclonal antibodies, and newer treatments like GLP-1 diabetes medications. These biologics require specialized containment systems because they are more sensitive to environmental factors and contamination than traditional chemical drugs.
Revenue model
Stevanato generates revenue primarily through product sales to pharmaceutical companies, with different margin profiles across its portfolio. The BDS segment operates on a manufacturing model where the company produces and sells physical containers and delivery systems, with gross margins typically ranging from 25-35%. Higher-value products like ready-to-use syringes and specialized biologics containers command premium pricing and margins of 35-45%, while bulk glass vials operate at lower margins of 15-25%. The Engineering segment follows a project-based model, selling manufacturing equipment and providing related services. This segment typically achieves gross margins of 10-20%, with after-sales services and spare parts providing higher-margin recurring revenue streams. Several factors influence the company's profitability. Positive margin drivers include the ongoing shift toward biologics in the pharmaceutical industry, which requires more sophisticated and higher-priced containment solutions. The trend toward ready-to-use products, driven by pharmaceutical companies' desire to reduce contamination risk and improve manufacturing efficiency, also supports premium pricing. Additionally, Stevanato's integrated approach - offering both containers and the equipment to fill them - creates customer stickiness and cross-selling opportunities. Margin pressures come from raw material cost inflation, particularly for glass and specialized materials used in high-value products. The company also faces periodic destocking cycles when pharmaceutical customers reduce inventory levels, as occurred during 2023-2024 following pandemic-related overordering. Competition from other packaging suppliers and the cyclical nature of pharmaceutical capital equipment spending can also impact margins. Currency fluctuations affect the company since it operates globally but reports in euros.
Competitive moat
Stevanato's competitive moat stems from several interconnected factors, though it faces meaningful competitive pressures. The company's primary moat lies in its integrated manufacturing capabilities - it both produces pharmaceutical containers and manufactures the specialized equipment needed to fill and inspect them. This integration creates customer switching costs, as pharmaceutical companies prefer suppliers who can provide end-to-end solutions and technical support throughout the product lifecycle. The company also benefits from regulatory barriers and quality certifications. Pharmaceutical packaging must meet stringent FDA and EMA requirements, and changing suppliers requires extensive validation processes that can take 12-24 months. Once Stevanato's products are validated for a specific drug, customers are reluctant to switch suppliers due to the time, cost, and regulatory risk involved. Technical expertise in biologics represents another competitive advantage. As the pharmaceutical industry shifts toward more complex biologic drugs, Stevanato's specialized knowledge in handling sensitive compounds and its ready-to-use solutions become increasingly valuable. The company has invested heavily in cleanroom manufacturing and specialized coating technologies that protect biologics from degradation. However, the moat faces several challenges. Large competitors like Schott AG and Gerresheimer have similar capabilities and global scale. The core glass vial business is relatively commoditized, with limited differentiation beyond quality and service. Additionally, some large pharmaceutical companies are developing in-house packaging capabilities or working with multiple suppliers to reduce dependence on any single vendor. The cyclical nature of pharmaceutical capital spending also creates periodic pressure on the Engineering segment's pricing power.
Risks & safety
Stevanato demonstrates a moderate margin of safety with solid fundamentals but some valuation concerns. **Financial Strength:** - Current ratio of 1.82 indicates adequate liquidity coverage - Debt-to-equity ratio of 0.28 shows conservative leverage - Cash position of €106 million provides operational flexibility - Positive free cash flow generation, though lumpy due to capital investment cycles **Valuation Metrics:** - P/E ratio of 48.6x appears elevated relative to industrial peers - EV/EBITDA of 23.8x suggests premium valuation - Price-to-book ratio of 3.6x reflects market confidence in growth prospects - Graham number analysis suggests potential overvaluation at current levels **Other Considerations:** - Strong recurring revenue base from pharmaceutical customers provides earnings stability - Significant capital expenditure requirements for facility expansion create near-term cash flow pressures - Exposure to pharmaceutical industry cycles and destocking events adds earnings volatility - Geographic diversification across Europe, US, and Asia provides some risk mitigation
Recent development
Over the past three years, Stevanato has pursued an aggressive capacity expansion strategy focused on high-value solutions and geographic diversification. The company has invested heavily in two major manufacturing facilities: a new plant in Latina, Italy, and a significant expansion of its Fishers, Indiana facility. The Fishers facility, which began commercial production in 2024, is expected to generate €500 million in annual revenue by 2028 and represents a strategic move to serve the US market domestically. The company has also shifted its product mix toward higher-margin "high-value solutions," which now represent 47% of BDS segment revenue, up from 30% in 2022. This includes ready-to-use vials, prefillable syringes, and specialized containers for biologics. Stevanato has particularly focused on the growing GLP-1 diabetes medication market and other biologic applications, with biologics now representing 42% of BDS revenue. In response to market challenges, the company implemented a business optimization plan for its Engineering segment in 2024, focusing on improving project execution and operational efficiency. The company has also launched an "Alliance for Ready-to-Use solutions" to strengthen its market position in sterile, ready-to-use packaging. Recent quarters have seen the company navigating a significant destocking cycle in the vial market, where pharmaceutical customers reduced inventory levels built up during the pandemic, leading to a 38-43% decline in vial revenues during 2024.
STVN company profile · for informational purposes only — not investment advice.
Track STVN with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free